Multiethnic radiogenomics reveals low-abundancy microRNA signature in plasma-derived

extracellular vesicles for early diagnosis and molecular subtyping of pancreatic cancer

Wenjie Shi[1,*], Jianying Xu[2,*], Yi Zhu[3,*], Chao Zhang[4,*], Julia Nagelschmitz[1], Maximilian Doelling[1],

Sara Al-Madhi[1], Ujjwal Mukund Mahajan[2], Maciej Pech[5], Georg Rose[6], Roland Siegfried Croner[1],

Guo Liang Zheng[7,*], Christoph Kahlert[8,*], Ulf Dietrich Kahlert[1,6,*,#]

[1] Molecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and

Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke

University, Magdeburg, Germany

[2] Department of Medicine II, Hospital of the LMU Munich, 81377, Munich, Germany

[3] Department of Gastroenterological Surgery, The Affiliated Hospital of Jiaxing University,

Jiaxing, Zhejiang, China.

[4] Department of Radiology, The First Affiliated Hospital of Wannan Medical College, Wuhu City,

Anhui Province, China

[5] Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg,

Germany

[6] Research Campus Stimulate, Otto von Guericke University Magdeburg, Germany

[7] Department of Gastric Surgery, Cancer Hospital of China Medical University (Liaoning Cancer

Hospital and Institute), Shenyang, China

[8] Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital,

Heidelberg, Germany

[*] equal contribution

[#] corresponding author: ulf.kahlert@med.ovgu.de

Key words: PDAC, EV, microRNA, CT, radiogenomics

Running title: microRNA signature for the diagnosis of pancreatic cancer

The authors declare no potential conflicts of interest

Abstract

Purpose

Pancreatic cancer is a highly aggressive tumor, and early diagnosis and treatment significantly

improves the clinical benefit for patients. However, currently there is a lack of effective methods

to accurately detect this disease. In our study, we develop a liquid biopsy signature of EV

miRNAs based on associated radiomics features of patients' tumors in order to provide new

insights for the early diagnosis of pancreatic cancer.

Experimental Design

A total of eight datasets enrolled in this study, featuring clinical and imaging data from different

benign pancreatic lesions and malignant pancreatic cancers as well as small RNAseq data from

cargo of plasma extracellular vesicles of tumor patients. Radiomics Feature Extraction and

different features analysis performed by limma packages. Feature selection was performed by

Boruta algorithms and radiomics related signature model was build and validated by lasso

regression algorithms. Radiomic signature related to low abundance EV miRNAs was analyzed

by weighted gene co-expression network analysis. The diagnosis ability of above miRNA are

validated by ten machine-learning algorithms. The shared target of candidate miRNAs were

predicted and clustered followed by subsequently probing for predicting survival benefit of the

patient, drug sensitivity of tumor cells and functional differences.

Results

A total of 88 significant radiologic features demonstrate differences between benign lesion and

pancreatic cancer. Three radiomics factor related signature related a plasma EV-miRNAs triplet

possessing high accuracy in diagnosis cancer from benign lesions. Moreover, clustering miRNA

and there predicted molecular signaling partners in tumor tissue identified tow molecular

subtypes of pancreatic cancer. Cluster stratification separates low risk tumors in terms of

severely prolonged overall survival time of patients, higher sensitivity to immune therapies. We

also propose the potential of purposing selected targeted drugs to specifically targeting the

molecular activation markers in high-risk tumor cluster.

Conclusion

Our three radiogenomics related blood plasma extracellular vesicle microRNA signature is a

useful liquid biopsy tool for early diagnosis and molecular subtyping of pancreatic cancer, which

might treatment decision making.

Statement of translational relevance

The identification of a low-abundance microRNA signature in plasma-derived extracellular

vesicles offers significant translational potential for the early diagnosis and subtyping of

pancreatic cancer, particularly across diverse ethnic populations. This discovery could lead to

the development of non-invasive liquid biopsies that improve early detection rates, a critical need

for a cancer with notoriously poor prognosis due to late diagnosis. By incorporating this

microRNA signature into clinical practice, oncologists may be able to detect pancreatic cancer at

earlier, more treatable stages, enhancing patient survival rates. Additionally, the subtyping

capability of this signature could guide personalized treatment strategies, allowing for more

targeted therapies based on specific cancer subtypes. This could ultimately reduce the need for

invasive diagnostic procedures and optimize treatment efficacy, reducing adverse effects and

improving outcomes. The integration of radiogenomics and liquid biopsy technologies promises

to be a powerful tool in the future of cancer medicine, particularly in underserved populations.

Introduction

Pancreatic cancer is one of the most lethal tumors having a poor prognosis and patients

suffering from this disease show one of the lowest 5-year overall survival rate of all cancer

patients with approximately 13%. One of the main reasons for this dismissal prognosis is the

lack of a proper early detection possibility, resulting in late diagnosing often in advanced,

metastatic stage[1]

The detection and diagnosis of pancreatic cancer, of which approximately 90% are classified as

pancreatic ductal adenocarcinoma (PDAC), currently relies primarily on modalities of medical

imaging, such as computer tomography, magnet resonance imaging, positron emission

tomography and transabdominal ultrasonography[2]. The most common biomarker considered for

PDAC differential diagnosis is elevated blood abundancy of carbohydrate antigen 19-9 (CA19-9)

and carcinoembryonic antigen (CEA), though these are only used as prognostic markers and not

effective for screening or early diagnosis[3] Nowadays, new markers based on liquid biopsy such

as microRNA are discerned and might pose as promising tools for early detection of PDAC.

miRNA are non-coding RNAs that target genes and regulate their expression by inhibiting mRNA

translation or enhancing their degradation[4]. Currently, extracellular vesicles (EV) are gaining

attention as disease specific marker since they carry the material of their secreting cells and are

therefore considered to contain tumor-derived elements, showcasing their molecular fingerprint

(Bamankar und Londhe 2023). It has been shown multiple times that miRNA derived from small

EVs play a role in differentiation and metastasis of cancer[5,6]. The rapidly developing field of data

mining and analytical techniques provide new insights and make the discovery of relevant key

players more feasible. Numerous miRNA have been described using co-expression network

analysis that might be applicated as diagnostic or prognostic biomarker, for patient stratification

or disease recurrence[7].

Benefiting from interdisciplinary advances in artificial intelligence, the integration of machine

learning and genomics has led to breakthroughs in the early diagnosis and classification of

tumors. For example, we used machine learning algorithms to assist in the development of a

three-serum miRNA signature that effectively provides early warning of premalignant pancreatic

cancer[8]. Another model, based on machine learning algorithms, focuses on the immune

subtypes of triple-negative breast cancer, offering critical insights for identifying patients who

may benefit from immunotherapy[9]. In the current study, we employed radiogenomics technology,

another product of interdisciplinary collaboration between medicine and engineering. This novel

approach integrates the quantification of image features from CT or MRI, which are then

correlated with genomic signatures and allows for a non-invasive prediction of molecular

characteristics[10]. Such as, claim to be able to predict the occurrence of p53 mutations using CT

images by radiogenomic analysis and hence make a statement on the prognosis[11].

In the present study, we aim to develop a liquid biopsy signature of EV-derived miRNA based on

the radiogenomic analysis of CT images derived from ethical diverse background and

interrogating small RNAseq data of plasma-derived total EVs, in order to advance the diagnostic

possibilities and the molecular subtyping of PDAC.

Materials and Methods

Data resources and pre analytics preparation

A total of four hospitals and four public datasets, comprising a total of eight datasets enrolled in

this study, University hospital Magdeburg in Germany (UMMD), and Jiaxing Hospital Center,

China (JHC), provided enhanced computed tomography (CT) images of 46 intraductal papillary

mucinous neoplasm (IPMN) patients and 127 pancreatic cancer (PC) patients as training dataset.

For test datasets, CT data resource from Wanan medical university hospital (WUH) with 27 PB

patients and 72 PC patients. University hospital Dresden, Germany (DUH) center provide

miRNA and mRNA seq data from total plasma extracellular vesicles (EV) of PDAC patients with

associated clinical follow information, including 20 benign pancreatic disease patients and 63

pancreatic cancer patients. The four public serum miRNA sequence data containing pancreatic

cancer (PC) and healthy control (HC) were GSE106817(2759 PC vs.115 HC), GSE113486(40

PC vs.100HC), GSE112264(50 PC vs.41 HC), GSE109319(24 PC vs. 21 HC). All CT images

were acquired using a 64-slice multidetector spiral CT scanner, with a standard slice thickness

of 1.0–1.5 mm and a reconstruction interval of 1 mm. All pancreatic cancer patients underwent a

standard pancreatic protocol triphasic contrast-enhanced CT examination. For radiomics

analysis, images from the portal venous phase were selected due to their consistent clarity in

delineating pancreatic tumor boundaries and surrounding vasculature. To ensure data

consistency, all imaging data underwent preprocessing, including resampling, intensity

normalization of grayscale values, and N4 bias field correction to address potential low-

frequency signal inhomogeneities. We use Propensity Score Matching (PSM) method to match

the begin and tumor patients from DUH to UMMD & JHC according to age factor. Afterwards, we

constructed a new matrix including CT images, EV miRNAs, mRNAs and patients clinical follow

up information. The workflow is schematically depictured in Figure 1. Ethical approval to conduct

the study for UMMD and DUH after approval by the local Institutional Review Board/ethics

committee (UMMD 46/22; 30/01 with amendment 43/14; DUH: EK76032013). Written informed

consent from the patients was obtained pre-operatively with the disclosure of research purpose.

Figure 1: Schematic presentation of the workflow of this study. The use radiomics to aid finding
novel EV charged miRNAs to allow PDAC diagnostics.

EV isolation and RNA sequencing

Details on the protocols for EV isolation including presentation of optical and molecular
characteristics of isolated vesicles proofing high quality isolation performance have been
described previously by our groups[12].

EV isolation using ultracentrifugation: 500 µl plasma samples were thawed and mixed with
500 µl PBS. The diluted plasma samples were filtered with 0.2 µm filter and subjected to
ultracentrifugation at 100,000×*g*, 2 h, 4 °C in a ultracentrifuge (Sorvall MX150□+□micro-
ultracentrifuge, Thermo Scientific, Darmstadt, Germany). The supernatant was removed and the
pellet was washed once with ice-cold Phosphate Buffered Saline (PBS, Gibco, Carlsbad,
California, USA) and ultracentrifuged again at 100,000×*g*, 2 h, 4 °C. The resulting pellet was
resuspended 100 µl PBS and transferred to Vivaspin ® 500 filtration (100,000 MWCO, Sartorius,
Göttingen, Germany) for centrifugation at 15,000×*g*, 45 min. The concentrated EVs were stored
at −□20 °C until further use for EV characterization.

EV isolation using precipitation method: 550 µl plasma samples were thawed and first
centrifuged at 2000×*g* for 20 min. The supernatant was subjected to another round of
centrifugation at 10,000×*g* for 20 min. After the second round of centrifugation, 500 µl
supernatant was mixed with 250 µl PBS, vortexed and added with 150 µl Exosome Precipitation
Reagent. The mixture was incubated at room temperature for 10 min and centrifuged at
10,000×*g* for 5 min. After removing the supernatant completely, the pellet was resuspended with
500 µl PBS and concentrated with Vivaspin ® 500 filtration (100,000 MWCO, Sartorius,
Göttingen, Germany) by centrifugation at 15,000×*g*, 45 min. The resulting EVs were stored at
−□20 °C until further use for EV characterization.

RNA sequencing

The eluted EV RNAs were first analyzed for their integrity and concentration using Agilent
Fragment Analyzer 5200™ with DNF-472 High Sensitivity RNA Analysis Kit, 15 nt (Agilent
Technologies, Santa Clara, California, United States). A range of 1 ng–2 µg RNA was used for
complementary DNA (cDNA) synthesis as a preparation for EV RNA sequencing (RNA-seq)
libraries with SMARTer smRNA-Seq Kit for Illumina (Takara Bio Inc, Mountain View, California,
USA) and were sequenced on an Illumina sequencing platform (NextSeq® 500/550 Mid Output

Kit v2, San Diego, California, USA) with run configurations of single read, read 1:51 cycles,

index 1:8 cycles, index 2:8 cycles and an average of 3.7 million reads per sample.

Raw reads were first converted from bcl to fastq format using bcl2fastq (v2.20.0.4.422) and

subsequently filtered using FastQ Screen to remove potential contaminations by microorganisms

or artefacts due to technical issues. The reads were mapped to a phase II reference genome of

the 1000 Genomes Project.

Radiomics Feature Extraction and different features (DFs) analysis

We use 3DSlice soft (www.slicer.org) to mark pancreatic benign and pancreatic cancer in CT

images as mask and use original figure as reference. Subsequently, we use python (Version 3.8)

soft to extract radiomics feature, respectively. Afterwards, we use limma packages analysis to

conduct different feature analysis to identify the significant features between benign and

cancer[13]. The p-value ≤ 0.05 was defined as statistical significant.

Feature selection and radiomics related signature model build

After obtain the DFs, to avoid multicollinearity of the data, we conduct the dimensionality

reduction analysis by Boruta algorithms and Lasso regression (LR) model. First, the Boruta

algorithms will calculate the importance of each feature and if importance more than shadow

feature, it will be selected as important feature, and then, input above important feature into the

LR model, the features were selected as significant if the model penalty coefficients were

minimized. After selection by machine learning algorithms, we calculate the regression

coefficient of each feature in LR model. After that, by combining the feature expression to build

the signature model in order to predict the images status from large amount of imaging data. The

model formula as listed below, Each regression coefficient of the features is multiplied by its

corresponding feature expression level, and then these products are summed. The resulting

sum is the Risk Score. The model validation was test with applying WUH center CT dataset,

whereas the area under curve (AUC) of Receiver operating characteristic curve (ROC） was

used to evaluated the predict ability of model.

Definition and identification of low abundance EV-derived miRNA transcripts.

Low abundance miRNAs are defined as the EV miRNAs with the lowest 30% Counts Per Million

(CPM) value across all samples. First, we calculate the CPM value for each miRNA across all

samples using the edgeR function[14]. Then, the non-zero miRNAs with CPM values ranked in the

lowest 30% of all samples were selected and defined as low abundance miRNAs

Weighted gene co-expression network analysis (WGCNA) analysis to identify imaging feature

related EV miRNAs

According to the radiomics signature, patients will be spilt into low and high-risk group. Low risk

classification means images have high percentage of feature parameters from benign images

while high risk more likely become cancer featuring images. To explore the correlation between

above groups with EV miRNAs, we conduct the WGCNA analysis. The soft-thresholding power

of WGCNA was automatically defined by the model, which was then assisting in calculating the

expression correlation with a) a given miRNA to obtain gene significance (GS), and b) of module

membership with miRNAs to obtain module membership (MM). Based on the cut-off criteria

($|MM| > 0.5$ and $|GS| > 0.1$), we obtain the significant miRNAs related to low and high risk

images, respectively.

Hub EV miRNAs identify and validation in serum and tissues level

We merge WGCNA results and low abundance EV miRNAs to identify the candidate hub

miRNAs, then we use GSE109319 to validate this EV miRNAs different expression between

healthy participants and PADC patients in serum level. In addition, we also validate this EV

miRNAs different expression between pancreatic tissue of healthy individuals and PADC tissues

in TCGA- sample cohort.

Screening the best models to aid hub EV miRNAs in blood based diagnosis

We collect serum dataset from GSE106817, GSE113486, GSE112264, our hospital center

(UMMD) and GSE109319 dataset to perform this procedure. First, the GSE106817 as training

dataset, GSE113486 and GSE112264 are used as independent test dataset. Then we use ten

machine learning algorithms (Gradient Boosting Machine

GBM ,KNN ,Lasso ,XGBoost ,ENR ,SVM ,LR ,RR ,StepWise ,and QDA) composition to select

the best model for prediction. After selection based on highest performance values, we apply our

hospital (UMMD) dataset and GSE109319 to validate the model accuracy for ability of clinical

prediction.

Common candidate target mRNAs of hub EV miRNAs

To discover the candidate regulation mechanisms of hub EV miRNAs, we use miRPathDB v2.0
database (https://mpd.bioinf.uni-sb.de/overview.html) to predict the candidate target mRNAs of
hub EV miRNAs. Subsequently we select the pass experiment validation mRNAs from the
evidence column, as candidate targets of each miRNAs. then, we explore candidate targets of
above which were regulated by this three miRNAs at the same time. Finally, we merge above
targets and DHU patient's mRNA sequence to identify the final shared mRNAs which were
regulated by three miRNAs at the same time and for the future analysis.

Cluster of shared target mRNAs and survival analysis between different clusters

We use R package ConsensusClusterPlus to perform the cluster analysis of common target
mRNAs, and rank the best cluster results according to the Consensus value output received.
Afterwards, we also analyze the survival difference between identified subtypes by R package
survival. OS and DFS were used to as event endpoint.

Clustering of tumor subtype with clinical factors

To explore the clinical value of each subtype, we analyze the relationship between the subtypes
and important clinical factors, such as, age, tumor size, number of positive lymph nodes. We
also discover the distribution of sex, peri-neural invasion (PNI), and tumor stage the in different
subtypes.

Characterization of immune cell infiltration properties and immune check point activation in each
tumor subtype

We use the Microenvironment Cell Populations-counter (MCP-counter) algorithms to calculate
immune cell infiltration of each samples and calculated the difference in the two tumor subtypes
for each immune cell type separately. We also conduct the relationship between the subtypes
and immune check point activation, to predict the candidate subtype could benefit from the
immune checkpoint inhibitors.

Potential drug sensitivity for each subtype

We download drug sensitivity data of molecular characterized cell lines to FDA approved, clinical

drugs from GDSC database https://www.cancerrxgene.org/ , and then use pRRophetic package

to estimate the drug sensitivity of the two discovered subtypes.

Functional enrichment analysis and pathway prediction

To explore the biological function difference in Biological Process (BP), Cellular Component (CC)

and Molecular Function (MF), we conduct the Gene Set Enrichment Analysis (GSEA) analysis.

We also use this method to analysis the pathway enrichment difference between the two

subtypes. Cluster profile package perform this operation and set p-value ≤ 0.05 as significant

enrichment results.

Results

Enrolled population and baseline information for CT images and EV miRNA

A total of 272 patients enrolled this study providing CT imaging, including 173 in UMMD&JHC

center while 99 in WUH center. In UMMD&JHC center, also including 46 pancreatic benign

lesion and 127 pancreatic cancer CT images. Most of pancreatic patients in this center are older

with obesity, but less smoking or alcohol and less with diabetes. For WUH center, most

pancreatic cancer are female, and also with a high account for older, and obesity. The DUH

provide the patients with EV-miRNAs, EV-mRNAs data and follow up information. About 82.5%

(52/63) patients are older, and 34 patients are female. The clinical characteristics of the data

cohorts are summarized in Figure 2.

Figure 2: The base line information of clinical parameters of patients enrolled from four centers
in this multi-center trial.The * means p less than 0.05,** means p less than0.01,and ***means p
less than0.001.

Different expression radiomic features between pancreatic benign lesions and aggressive
tumors

Before the analysis, we conduct the PSM procedure to match the benign and aggressive tumor
from DUH to JHC, respectively, according to age. After match, we found both center baseline
difference are removed (Figure 3A). Then the difference expression radiomics features was
conduct, the results indicate that a total of n=88 significant features demonstrate differences
between groups (Figure 3B).

Figure 3: Propensity Score Matching (PSM) allows matching data of benign pancreas lesions
and PDAC patients from DUH to UMMD & JHC patients according to the age factor, all of DUH
patients successful matched similar patients (A). The different radiomic features between the
benign lesions and PDAC patients CT images(B). 12 most important radiomic features
differentiating between the benign pancreatic lesion and PDAC patients´ CT images identified by
the Boruta algorithms (C) Four radiomic features were selected by Lasso Regression to build

model signature (D&E). Applying the four radiomic features related signature in image analysis

show high accuracy in predicting the PDAC manifestation in the WUH test dataset(F).

Four important radiomic feature was selected to build a related signature

We use Boruta algorithms to select the important features and result show that a total 12

features were identified(Supplement Table 1), which more than shadow features. In addition,

after input above features into LR algorithms and we can found that four features are list as key

features(Figure 3C-D). Based on LR model with regression coefficient and feature expression,

we build a four radiomics feature related signature and validate the prediction ability in WUH

center data, revealing a signature accuracy of prediction efficiency (AUC=0.911) (Figure 3E-F).

Supplement Table 1 Important radiomic features

Id	Detail inforamtion of features
f_1	wavelet.HHH_ngtdm_Contrast
f_2	wavelet.HHH_glcm_SumAverage
f_3	wavelet.HHH_glcm_JointAverage
f_4	wavelet.LLL_firstorder_Kurtosis
f_5	wavelet.HLH_firstorder_Uniformity
f_6	wavelet.HHH_firstorder_Minimum
f_7	wavelet.HLH_firstorder_Entropy
f_8	wavelet.LLH_firstorder_Mean
f_9	wavelet.LLH_firstorder_Median
f_{10}	wavelet.HLL_firstorder_Median
f_{11}	log.sigma.1.mm.3D_glszm_GrayLevelNonUniformity
f_{12}	wavelet.HLH_firstorder_10Percentile

Three EV miRNAs are associated with radiomic features

After radiomics signature was build, each patients presents an individual risk score and we split

patients into high-risk and low-risk patients, according to median value of risk score. We use

WGCNA to connect the EV miRNA data and two imaging-featured patient risk groups. According

to the WGCNA analysis, the green module was identified as the key module and includes 12

hub co-expressed miRNAs. The number of low abundance of miRNA are calculated was n=295.

Merging both results, three miRNAs are identified (hsa-miR-1260b, hsa-miR-151a-3p and hsa-

miR-5695) and selected for subsequent alignment with associated with radiomic features (Figure

4A-C).

Expression validation of three EV miRNAs

We use serum and tissues sample to validate the expression of three hub EV miRNAs and the

results show that compare with healthy serum sample, this three miRNAs are enriched in tumor

patient serum sample. Interestingly, this correlation of upregulation in tumor conditions was also

true when comparing tumor tissue with non-tumor tissue (Figure 4D-I).

Figure 4:EV miRNA presenting the risk group stratification based on radiomics signature by WGCNA analysis featuring green mode discovering our key module for further analysis (r=0.21, p=0.047) (A). The number of low abundance miRNA in the entire EVseq dataset cohort is n= 295 (B). Out of those low abundance miRNAs, n=12 present matching candidates differentially expressed in high risk group patients. Alignment to our radiomics feature parameters identified three core miRNAs (hsa-miR-1260b, hsa-miR-151a-3p and hsa-miR-5695) (C). The three key miRNAs show significantly different expression levels in tumor condition, both for serum (D-F) and tissue (G-I).

Three EV miRNAs predictd pancreatic cancer with high accuracy

We use seven machine-learning combos to train and test the ability of three EV miRNAs levels to predict tumor manifestation and clinical course of patient. The results show that in the GBM-default (cutoff=0.75) model, three EV miRNAs show a high accuracy to predict the pancreatic cancer with the training accuracy was 0.978 with AUC=0.978, and two test dataset accuracy are 0.923 with AUC=0.919, and 0.871 with AUC=0.857,respectively. Then, we choose GBM model for the extend validation by our hospital data(MUH) and GSE109319.Before this procedure, we use combat package to remove the batch effect allowing the merge of the two datasets. The results of the extend dataset validation via GBM further highlights the high diagnostic accuracy of the three EV miRNAs (accuracy =0.894, and AUC=0.897) (Figure 5), while the CA19-9 predict auc is 0.843(95% CI, 0.762–0.924).

Figure 5: Ten machine learning algorithms demonstrate that three key miRNAs show a high accuracy to diagnosis PDAC in early stage, no matter in training or test datasets. The best machine learning algorithms is GBM (cutoff:0.75) (A). Three miRNAs prediction ability of training

dataset (GSE10106817) in GBM model is 0.978(B). Three miRNAs prediction ability of test

dataset (GSE113486 and GSE112264) in GBM model is 0.919, and 0.857, respectively(C&D).

Data distribution before removal of batch effect of our center data and GSE109319 dataset (E).

Data distribution after remove batch effect of our center and GSE109319 dataset (F). Three EV

miRNAs prediction ability to identify cancer of our center data and GSE109319 in GBM model is

0.897(G).

Identification of two molecular subtypes of PDAC with significant clinical predictive value

After predicting molecular targets of three miRNAs, we obtain a number of 117 mRNA are

shared candidate targets (**Supplement Table 2**). Stratifying the tumors according to the level of

expression of those allows the differentiation of tumors in cluster into two subtypes termed

Cluster 1 (C1) and C2 (Figure 6A and Supplement Figure 1). The survival analysis show that

compared with C1, the C2 patients feature a prolonged survival outcome, no matter in OS or

DFS(Figure 6 B&C). In addition, analysis the relationship with clinical factors of patients, we also

found the C1 subtype patients are older in age and carry bigger tumor sizes and higher number

of tumor cell positive lymph nodes(Figure 6D-F), while compared with C2 subtype patients. We

also demonstrate C1 patients particular aggressive in female patients, feature high number of

tumors containing perineural invasion (PNI) and advanced pathological tumor staging (Figure 6

G-I).

Figure 6: Stratification of abundancy levels of shared mRNAs by Non-negative matrix
factorization method allows the clustering of patients into two subtypes (C1 and C2) (A). Patients
of the C1 with a poor out outcome in OS and DFS(B&C). C1 subtype patients are characterized
with older age and bigger average tumor size, higher number of tumor cell positive lymph nodes
as compared to C2 patients (D-F). C1 patients are predominantly female, have tumors with
pathological classification marks of perineural invasion and advanced tumor stage (G-I).

Supplement Table 2 Shared targets of three EV miRNAs

hsa-miR-1260b	hsa-miR-151a-3p	hsa-miR-5695
Candidate Targets		
AATF,AZIN2,CABIN1,CECR2,DENND4B,EIF3B,EMB,FKBP15,GLMN,HADH,IKBKB,MLH3,MRPS21,		

NDE1,PIM3,PLEKHA2,PSMF1,PUM1,RNF125,SAE1,SAP30BP,SLC6A6,TCOF1,USP36,YWHAQ,A
SCL5,CCDC140,CHEK2,DAPK2,FAM71F2,GIGYF2,HEATR5A,HIST1H2BJ,MPHOSPH9,NFASC,PC
BD2,PRR13,SGK3,SH3PXD2A,SLC22A3,STON2,TOMM40,ZNF398,ZNF791,ABI2,ACAT1,ALDOA,A
PLP2,ATAD1,AUTS8,C16orf58,C2orf48,CCT7,CDCA4,CDKN1A,CKB,CLCN2,COL4A3BP,COPA,CT
PS1,DDX3Y,DHX30,DNAH10OS,DNMT1,EEF1A1,EIF4G1,ENO1,EPHB4,EZH2,GAN,HIPK1,HNRNP
A2B1,HNRNPA3,IKZF2,LGALS3BP,MCM7,MDN1,MKNK2,MRPL24,MRPL37,MYO5C,NBPF15,NCA
PG2,NFE2L1,NOL8,OGG1,PALM2,PARP4,PLOD2,POLR2A,POLR3D,PPIAL4A,PRC1,PRKRIP1,PT
PRF,RAB19,RAB5IF,RBMXL1,RPE,RPL3,RPL36A,RPL4,RPS15,RPS6,RPS7,SEC61G,SETDB1,SF
3B1,SLC25A3,SLC39A8,SLC3A2,SLC7A5,SOGA3,SP3,TMEM59,USP12,WDR62

C2 patients with high immune infiltration and positive with immune checkpoints

Testing for gene signatures that indicate immune cell existence, we show that C2 tumors are

significantly more enriched for immune cell signals, including those for CD8 T cells, Cytotoxic

lymphocytes and NK cells (Figure 7 A&B). In addition, samples of patients of that subtype show

also a more physiological expression signature in terms of immune checkpoints as compared to

C1 tumors (Figure 7C).

Prediction of drug sensitivity of C1 patients

We use Genomics of Drug Sensitivity in Cancer (GDSC) data to merge cell line response data

and expression data with expression signals in C1 and C2 tumors. This analysis indicated that

C1 patients may benefit from therapy with FDA approved AKT inhibitor VIII, Bleomycin,

Dasatinib, GNF-2, PF -562271, Refametinib, BMS-509744 (Figure 7E).

Figure 7: C2 subtype is positively associated with elevated levels of transcripts regulating gene pathways encoding for CD8 T cells, cytotoxic lymphocytes, NK cells(A&B). Commonlyknown immune checkpoints also higher expressed in C2 subtypes(D). Aligning in vitro drug sensitvtiy and expression data from the GDSC database to subtype signature, predicts that tumors of C1 patients might be more sensitive to AKT INHIBITOR VIII, Bleomycin, Dasatinib, GNF-2, PF - 562271, Refametinib, BMS-509744 as C2 subtypes.

Functional annotation and pathway enrichment for C1 subtype

GO functional enrichment analysis indicated that the C1 subtype is enriched for intermediate filament organization, GOCC ribosome, as well as GOMF symporter activity (Figure 8 A&B). Pathway enrichment analysis showed that the C1 subtype was activated with the Reactome fatty acids, Reactome diseases of metabolism, as well as Reactome biological oxidations pathways, and may be inhibited with Reactome apoptosis, Reactome DNA repair, and Reactome signaling by Hippo pathways (Figure 8C).

Figure 8: GO functional enrichment analysis indicated that the C1 subtype is enriched for intermediate filament organization, CC ribosome, as well as MF symporter activity(A-C). Pathway enrichment analysis showed that the C1 subtype was activated with the Reactome fatty acids, Reactome diseases of metabolism, as well as Reactome biological oxidations pathways, and may be inhibited with Reactome apoptosis, Reactome DNA repair, and Reactome signaling by Hippo pathways (D-I).Discussion

Using multicenter radiomics of Asian and Western world patients, we identified 3 plasma total extracellular vesicle fraction microRNAs that demonstrated strong predictive performance and prognostic value, offering new insights for noninvasive early diagnosis and prognosis of pancreatic cancer. This study is the first to distinguish between benign lesions and pancreatic cancer by identifying novel and significant plasma extracellular vesicle microRNAs based on differential radiomics features. We focused on low-abundance microRNAs, which are often overlooked in routine RNA sequencing analyses. These 3 microRNA candidates were validated across multiple cohorts, achieving excellent predictive performance in both testing and external

validation sets. Additionally, these microRNAs demonstrated prognostic value, potentially aiding

in treatment selection.

Pancreatic cancer remains one of the most lethal diseases, with insufficient early detection

methods and limited treatment options[15,16]. This study aimed to develop a liquid biopsy nucelaic

acid diagnsotic test based in EV-derived microRNA using radiogenomic analysis to enhance

diagnostic accuracy and molecular subtyping of pancreatic ductal adenocarcinoma. By focusing

on imaging features to distinguish benign lesions from pancreatic cancer, we identified

underlying genetic factors contributing to these differences. Unlike previous studies on serum

microRNA[17,18], our research identified three microRNAs through radiomics that reflect tumor-

specific changes rather than systemic variations. Additionally, our findings reveal relationships

between imaging features and tumor biology, improving diagnostic accuracy and offering a more

comprehensive tool for early detection and personalized disease management.

Although numerous studies have reported on microRNA sequencing results[19], highly abundant
microRNAs often mask the signals of many others that are present at very low abundance during
routine analysis. Furthermore, if a microRNA is associated with tumor development, it is likely to
be in low abundance during early detection and may even be undetectable in benign lesions. In
our study, after identifying 12 microRNAs related to radiomic differences, we further defined
three (hsa-miR-1260b, hsa-miR-151a-3p and hsa-miR-5695) of them as being of low abundance.
These microRNAs showed significantly higher expression in pancreatic cancer blood than in non
malignant cancer patients' plasma, with hsa-miR-1260b and hsa-miR-5695 undetectable in
pancreatic cancer samples. The model based on these 3 microRNAs demonstrated strong
performance in the training group (AUC, 0.978; sensitivity, 0.97; specificity, 0.99), testing group
(AUC, 0.919; sensitivity, 0.96; specificity, 0.88), and external testing group (AUC, 0.897;
sensitivity, 0.90; specificity, 0.89).

Previous studies on microRNAs as diagnostic biomarkers for pancreatic cancer vs healthy
controls report AUCs of 0.78-0.96 and sensitivities of 0.62-0.88[19], but many lack external
validation[20,21]. One case-control study identified 2 diagnostic panels based on microRNA
expression (index I: 4 microRNAs; AUC, 0.86; sensitivity, 0.85; specificity, 0.64; index II: 10
microRNAs; AUC, 0.93; sensitivity, 0.85; specificity, 0.85) [22]. Our study achieved similar
performance using only 3 microRNAs, making it more practical for clinical application.

To the best of our knowledge, hitherto none of the three identified microRNAs have been
reported in the context of diagnostic biomarkers in pancreatic cancer. Moreover, to our
knowledge, hsa-miR-5695 only indirectly been linked to breast carcinogenesis[23] and subtypes of
metastatic prostate cancer[24], while hsa-miR-1260b has been implicated in promoting
tumorigenesis in lung cancer[25], breast cancer[26], sarcoma[27] and prostate cancer[28]. Interestingly, in
a screen of microRNAs that are differentially expressing in total plasma fraction of patients
suffering from intraductal papillary mucinous neoplasm (IPMN) as compared to non-diseased
controls, hsa-miR-1260b was identified as one of the top upregulated signals in plasma of IPMN
cases[29]. Our work further enforces the potential of hsa-miR-1260b abundancy in plasma to detect
onset of abnormal pancreas genesis. Exosomal hsa-miR-151a-3p has emerged as a potential novel

biomarker for predicting bone metastasis in lung cancer[30]. A very recent report of results of
multicenter trial in Asian participants also identified circulating 2'-O-methylated form of hsa-
miR-151a-3p is upregulated in total fraction of plasma of PDAC patients compared to those
derived from healthy donors or patients with chronic pancreatitis[31]. Focusing on EV fraction, our
results verifies the potential of this newly discovered biomarker in pancreatic cancer blood
diagnosis.

Pancreatic cancer currently has only two standard systemic treatments with limited efficacy, and

the patient population responsive to immunotherapy and targeted therapy remains unclear[32].

Therefore, we explored the prognostic value of these microRNAs, which allowed for patient

stratification. Patients classified as C2 had better prognoses, with higher immune cell infiltration

and more immune checkpoint expression, suggesting they may be suitable for immunotherapy

after standard treatment. In contrast, patients classified as C1 had poorer prognoses, related to

inhibited pathways such as DNA repair and apoptosis.

The findings suggest potential for developing kits for early detection and treatment stratification,

and highlight these three candidates for further exploration. However, despite thorough matching

of imaging, genomic, and clinical data, biases may still exist. Additionally, using the MCP-

counter algorithm for blood samples is a limitation of our study, as it was originally designed for

solid tissues, which may affect the accuracy of cell population quantification in the blood.

Furthermore, when validating the three microRNAs in tissue, the sample size of paracancerous

tissue was limited. Lastly, since our EV purification did not use measures to enrich for cancer

cell derived EVs such as CD147 membrane presenting amplitude[33], we cannot exclude

contamination of our miRNA data due to signals from non-cancer cell background, which might

impact the cancer specificity of our proposed blood test. Moreover, our data is based on OMICS

data acquisition. Real world application of our proposed test would benefit from proofing the

predictability and sensitivity of the miRNAs by targeted methods, such as RT-qPCR or

CRISPR/Cas diagnostics and in prospective, multicenter trial. In addition, We acknowledge the

absence of third-phase validation results, which will limit application in the clinical practice.

Data availability

All data generated from this study, if not included in this article, are available from the

corresponding authors on reasonable request.

Funding

Authors contribution

Data acquisition and experiments, data analysis, layout: WS, IZ, GZ,

Resources: UDK, CK; RSC, GR, MP, GLZ

Data interpretation, writing and review manuscript: all authors

References

1   Bamankar, S. & Londhe, V. Y. The rise of extracellular vesicles as new age biomarkers
in cancer diagnosis: promises and pitfalls. *Technology in Cancer Research & Treatment* **22**,
15330338221149266 (2023).

2   Wang, S. *et al.* The molecular biology of pancreatic adenocarcinoma: translational
challenges and clinical perspectives. *Signal transduction and targeted therapy* **6**, 249 (2021).

3   Bestari, M. B., Joewono, I. R. & Syam, A. F. A Quest for Survival: A Review of the Early
Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present. *Biomolecules*
14, 364 (2024).

4   Rashid, S. *et al.* Elucidating the Role of miRNA-326 Modulating Hedgehog Signaling in
Pancreatic Carcinoma. *Pancreas* **53**, e42-e48 (2024).

5   Mok, E. T., Chitty, J. L. & Cox, T. R. miRNAs in pancreatic cancer progression and
metastasis. *Clinical & Experimental Metastasis*, 1-24 (2024).

6   Min, L. *et al.* Evaluation of circulating small extracellular vesicles derived miRNAs as
biomarkers of early colon cancer: a comparison with plasma total miRNAs. *Journal of*
extracellular vesicles **8**, 1643670 (2019).

7   Tiwari, P. K. *et al.* Extracellular Vesicular miRNA in Pancreatic Cancer: From Lab to
Therapy. *Cancers* **16**, 2179 (2024).

8   Shi, W. *et al.* Integrating a microRNA signature as a liquid biopsy-based tool for the early
diagnosis and prediction of potential therapeutic targets in pancreatic cancer. *British Journal of*
Cancer **130**, 125-134 (2024).

9   Chen, Z. *et al.* A machine learning model to predict the triple negative breast cancer
immune subtype. *Frontiers in immunology* **12**, 749459 (2021).

10   Casà, C. *et al.* The impact of radiomics in diagnosis and staging of pancreatic cancer.
Therapeutic advances in gastrointestinal endoscopy **15**, 26317745221081596 (2022).

11   Iwatate, Y. *et al.* Radiogenomics for predicting p53 status, PD-L1 expression, and
prognosis with machine learning in pancreatic cancer. *British Journal of Cancer* **123**, 1253-1261
(2020).

12   Han, Y. *et al.* Plasma extracellular vesicle messenger RNA profiling identifies prognostic
EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic
ductal adenocarcinoma. *Journal of Hematology & Oncology* **16**, 7 (2023).

13   Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing
and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).

14   Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140
(2010).

15   Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer:
Advances and challenges. *Cell* **186**, 1729-1754 (2023).

16   Fahrmann, J. F. *et al.* Lead-Time Trajectory of CA19-9 as an Anchor Marker for
Pancreatic Cancer Early Detection. *Gastroenterology* **160**, 1373-1383.e1376 (2021).

17   Wei, J., Yang, L., Wu, Y. N. & Xu, J. Serum miR-1290 and miR-1246 as Potential
Diagnostic Biomarkers of Human Pancreatic Cancer. *J Cancer* **11**, 1325-1333 (2020).

18   Shams, R. *et al.* Identification of potential microRNA panels for pancreatic cancer
diagnosis using microarray datasets and bioinformatics methods. *Sci Rep* **10**, 7559 (2020).

19   Yang, J. *et al.* Early screening and diagnosis strategies of pancreatic cancer: a
comprehensive review. *Cancer Commun (Lond)* **41**, 1257-1274 (2021).

20   Liu, J. *et al.* Combination of plasma microRNAs with serum CA19-9 for early detection of
pancreatic cancer. *Int J Cancer* **131**, 683-691 (2012).

21   Wang, Z. Diagnostic performance for declined microRNA-133a in pancreatic cancer. *J
Cell Biochem* **121**, 3882-3886 (2020).

22   Schultz, N. A. *et al.* MicroRNA biomarkers in whole blood for detection of pancreatic
cancer. *Jama* **311**, 392-404 (2014).

23   Søkilde, R. *et al.* Refinement of breast cancer molecular classification by miRNA
expression profiles. *BMC genomics* **20**, 1-12 (2019).

24   Watahiki, A. *et al.* MicroRNAs associated with metastatic prostate cancer. *PloS one* **6**,
e24950 (2011).

25   Kim, D. H. *et al.* Exosomal miR-1260b derived from non-small cell lung cancer promotes
tumor metastasis through the inhibition of HIPK2. *Cell Death Dis* **12**, 747 (2021).

26   Park, S. *et al.* Promotion of tumorigenesis by miR-1260b-targeting CASP8: Potential
diagnostic and prognostic marker for breast cancer. *Cancer Sci* **113**, 2097-2108 (2022).

27   Morita, T. *et al.* Clinical relevance and functional significance of cell-free microRNA-
1260b expression profiles in infiltrative myxofibrosarcoma. *Scientific reports* **10**, 9414 (2020).

28   Hirata, H. *et al.* Genistein downregulates onco-miR-1260b and upregulates sFRP1 and
Smad4 via demethylation and histone modification in prostate cancer cells. *Br J Cancer* **110**,
1645-1654 (2014).

29   Permuth-Wey, J. *et al.* Plasma MicroRNAs as Novel Biomarkers for Patients with
Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res (Phila). 2015; 8 (9):
826–34. In: (Epub 2015/09/01. https://doi. org/10.1158/1940-6207. CAPR-15-0094 PMID:
26314797).

30   Zhao, K. *et al.* Exosomal hsa-miR-151a-3p and hsa-miR-877-5p are potential novel
biomarkers for predicting bone metastasis in lung cancer. *Aging (Albany NY)* **15**, 14864-14888
(2023).

31   Yang, Z. *et al.* Contribution of a Circulating 2'-O-methylated MicroRNA Panel to the
Diagnosis of Pancreatic Ductal Adenocarcinoma. *Journal of Cancer* **15**, 1583 (2024).

32   Neoptolemos, J. P. *et al.* Therapeutic developments in pancreatic cancer: current and
future perspectives. *Nat Rev Gastroenterol Hepatol* **15**, 333-348 (2018).

33   Ko, S. Y. *et al.* The glycoprotein CD147 defines miRNA-enriched extracellular vesicles
that derive from cancer cells. *Journal of Extracellular Vesicles* **12**, 12318 (2023).

NMF rank survey

Factorization rank